Blurred Vision After Cataract Surgery: Causes, Diagnosis, and Management of Cystoid Macular Edema

After cataract surgery, some patients may notice that their vision becomes blurred again. This can occur for several reasons. One of the most common causes developing 6 months to 2 years after surgery is posterior capsule opacification (PCO), in which the lens capsule becomes cloudy. Another important and relatively common cause, especially within the first month after surgery but sometimes occurring months or even years later, is cystoid macular edema (CME), also known as Irvine Gass syndrome.

 

Cystoid macular edema is a condition in which fluid accumulates in the macula, particularly around the fovea, the area responsible for the sharpest central vision. This fluid collects within cyst-like spaces in the retina, most commonly in the inner nuclear layer and outer plexiform layer, causing swelling and distortion of the retinal architecture. As a result, patients may experience reduced vision, blurred central vision, and image distortion, also known as metamorphopsia.

 

The most common cause of CME in this setting is inflammation after cataract surgery, referred to as Irvine Gass syndrome. Surgical trauma can trigger the release of inflammatory mediators, including prostaglandins, which increase vascular permeability and allow fluid to leak into the macula. The risk may be higher in difficult or complicated surgeries with more postoperative inflammation. In some glaucoma patients, certain medications may also increase the likelihood of CME, so ophthalmologists must monitor these cases carefully when cataract surgery is planned.

 

Other retinal conditions can also contribute to the development of CME. These include diabetic retinopathy, retinal vein occlusion, and epiretinal membrane. In patients with diabetes, it is important to optimize systemic control before surgery, and in selected cases, preventive treatment may be considered to reduce the risk of postoperative macular edema. CME may also occur in patients with uveitis, in which inflammation causes breakdown of the blood-retinal barrier through cytokine-mediated mechanisms. For patients with a history of intraocular inflammation who require cataract surgery, careful perioperative management is essential.

 

Certain medications have also been associated with CME. These include prostaglandin analogs used for glaucoma, such as latanoprost, and more rarely niacin. Important risk factors for CME include diabetes mellitus, complicated cataract surgery, posterior capsule rupture during surgery, and pre-existing retinal disease.

 

Clinically, patients with CME often present with blurred vision after surgery, typically within 4 to 8 weeks, although early blurred vision in the first month is particularly important to recognize. They may complain of central blurring, distorted vision, or visual recovery that is worse than expected after surgery.

 

The diagnosis of CME is usually confirmed with optical coherence tomography (OCT), which is considered the gold standard. OCT can clearly demonstrate cystic spaces in the macula and increased central retinal thickness. Another useful diagnostic tool is fluorescein angiography (FA), which may show a characteristic petaloid leakage pattern.

 

Treatment is generally approached step by step. First-line therapy usually consists of topical nonsteroidal anti-inflammatory drugs (NSAIDs), such as nepafenac, combined with topical corticosteroid eye drops, such as prednisolone acetate. This combination is often more effective than either treatment alone. If there is insufficient response, the next step may include periocular or intravitreal steroid treatment, such as sub-Tenon steroid injection or intravitreal triamcinolone. In cases associated with diabetic macular edema or retinal vein occlusion, intravitreal anti-VEGF injections may be considered. It is also essential to address the underlying cause whenever possible, such as controlling uveitis, discontinuing the causative medication, or performing surgery for an epiretinal membrane if indicated.

 

The prognosis for CME is generally favorable. Most patients improve within 2 to 4 months, although some cases may become chronic and result in incomplete visual recovery.

 

An important clinical point is that when a patient reports blurred vision after cataract surgery, the problem should not automatically be assumed to be PCO alone. CME must always be ruled out with OCT, as both conditions can coexist. If a YAG laser capsulotomy is performed for presumed PCO without recognizing underlying CME, the condition may worsen.

 

In summary, cystoid macular edema is a significant cause of blurred vision after cataract surgery, resulting from inflammatory fluid accumulation in the macula. The mainstay of treatment is topical NSAIDs combined with corticosteroids, with escalation depending on severity and the underlying cause. Early diagnosis is essential to achieve the best possible visual outcome.

 

 

Source :  Ateye Clinic by Wanumkarng.